The differing species-specificity profiles of our preclinical antibodies provided us with a unique opportunity to compare the effects of inhibiting tumor-derived (human) and stromal-derived (mouse) MMP9 either singly or in combination in the HCT116 xenograft tumor model. This evidence concerns the gene MMP9 and neoplasm.